Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009021 | 0.88 | HRH3 (0.37) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL20009058 | 0.88 | HRH3 (0.37) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL20008995 | 0.88 | HRH3 (0.37) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL25540028 | 0.87 | SMN1; SMN2 (0.39) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL22255419 | 0.82 | SMN1; SMN2 (0.38) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL27204244 | 0.80 | SMN1; SMN2 (0.40) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL20008992 | 0.80 | SMN1; SMN2 (0.40) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL16869402 | 0.80 | SMN1; SMN2 (0.40) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL27157659 | 0.80 | SMN1; SMN2 (0.40) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 | |
| SCHEMBL20009022 | 0.80 | SMN1; SMN2 (0.40) | HRH3CYP2D6KCNH2SMN1; SMN2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | HRH3 203/4885CYP2D6 4116/4885KCNH2 3885/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HRH3 203/4885CYP2D6 4116/4885KCNH2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.